However, long-term use of statins has been confirmed to cause an increase in hyperglycemic adverse events (HAEs), including impaired fasting plasma glucose (FPG), increased glycated haemoglobin (HbA1c), and even new-onset diabetes (NOD), through various mechanisms such as inhibiting plasma glucose uptake, promoting insulin resistance, and inhibiting insulin secretion (1, 2). This evidence concerns the gene INS and dentatorubral-pallidoluysian atrophy.